NLRP3 and osteoarthritis: Osteoarthritis: Preclinical study demonstrated that exogenous miR-223 can inhibit NLRP3 inflammasome activation and chondrocyte pyroptosis, showing promising results for the treatment of OA (152)Acute gouty arthritis: Preclinical study demonstrated that miR-223-3p can inhibit NLRP3 expression, leading to a reduction in gouty inflammation (153)